Valuation: Wockhardt Limited

Market Cap 301B 3.1B 2.73B 2.54B 2.33B 4.37B 4.45B 30.32B 11.83B 147B 11.65B 11.4B 509B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 316B 3.26B 2.87B 2.67B 2.45B 4.6B 4.68B 31.89B 12.44B 154B 12.25B 11.99B 535B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-0.63%
1 week-2.14%
Current month-4.72%
1 month-8.15%
3 months+27.54%
6 months+35.96%
Current year+27.90%
1 week 1,825
Extreme 1825
1,950
1 month 1,792.4
Extreme 1792.4
2,058.2
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%-2.14%+8.09%+660.57% 3.13B
+0.57%+0.13%+16.45%+78.10% 48.31B
+0.55%-0.41%+67.13%+107.90% 35.33B
-1.56%-3.13%-4.88%+32.80% 11.85B
-1.11%-3.73%+16.41%+81.64% 11.64B
-0.37%-0.19%+36.48%+136.73% 8.99B
-0.56%+0.42%+51.66%-6.22% 6.93B
-0.77%-3.00%+13.55%+32.01% 6.72B
+0.24%-4.02%+2.19%+192.78% 6.43B
+1.60%-9.55%-30.77%+8.47% 5.66B
Average -0.28%-1.71%+17.63%+132.48% 14.5B
Weighted average by Cap. -0.16%-0.94%+27.18%+94.37%

Financials

2025 2026
Net sales 30.35B 313M 276M 256M 236M 442M 450M 3.06B 1.19B 14.8B 1.18B 1.15B 51.36B 34.62B 357M 314M 292M 269M 504M 513M 3.49B 1.36B 16.89B 1.34B 1.31B 58.58B
Net income -470M -4.85M -4.27M -3.97M -3.65M -6.84M -6.96M -47.42M -18.5M -229M -18.22M -17.83M -795M 2.13B 21.99M 19.34M 17.97M 16.53M 31M 31.55M 215M 83.82M 1.04B 82.57M 80.79M 3.6B
Net Debt 14.33B 148M 130M 121M 111M 209M 212M 1.45B 564M 6.99B 556M 544M 24.25B 15.53B 160M 141M 131M 121M 226M 230M 1.57B 611M 7.57B 602M 589M 26.28B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-07-23 ₹1,849.70 -0.63% 498,914
26-07-22 ₹1,861.50 -1.84% 801,530
26-07-21 ₹1,896.30 -1.41% 296,564
26-07-20 ₹1,923.40 +1.19% 959,200
26-07-17 ₹1,900.70 +1.30% 683,574
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock